A20-OVA Nanoparticles Inhibit Allergic Asthma in a Murine Model
- 40 Downloads
The skewed T helper (Th) 2 response plays a critical role in the pathogenesis of allergic asthma. Regulatory T (Treg) cells and the regulatory cytokines are required in maintaining the homeostasis in the body. This study aims to determine the effects of a poly(lactic-co-glycolic) acid (PLGA)-ovalbumin (OVA)+A20 (a ubiquitin E3 ligase) nanovaccine on inhibiting allergic asthma in a murine model. In this study, A20 and OVA (a model antigen) were encapsulated into PLGA to be a nanovaccine (PLGA-OVA+A20). An allergic asthma murine model was developed with OVA as the specific antigen to test the role of PLGA-OVA+A20 nanovaccine in maintaining the immune homeostasis in the airway tissues. The results showed that PLGA-OVA+A20 nanovaccine inhibited the asthma responses in mice by suppressing Th2 inflammatory responses, promoting the generation of Treg cells in the airway tissues. We conclude that the PLGA-OVA+A20 nanovaccine has a marked inhibitory effect on the airway allergic response in sensitized mice by significantly promoting the generation of Treg cell and IL-10. The data suggest that PLGA-OVA+A20 has translational potential in the treatment of allergic asthma.
KEY WORDSallergic asthma A20 nanovaccine Th2 response regulatory T cell
XQL, JWZ, SYQ, LQY, ZYL, MZ, and FXZ performed the experiments, analyzed the data, and reviewed the manuscript. LHM, DBL, and PCY organized and supervised the experiments. LHM and DBL designed the project and prepared the manuscript. PCY reviewed and edited the manuscript.
This study was supported by grants from the National Nature and Science Foundation of China (81701589), the Miao-Miao plan of Shenzhen Hospital, Southern Medical University (2017MM05), and Guangdong Nature Science Foundation (2016A030310248; 2014A020212569).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no competing interests.
- 14.Schuijs, M.J., M.A. Willart, K. Vergote, D. Gras, K. Deswarte, M.J. Ege, F.B. Madeira, R. Beyaert, G. van Loo, F. Bracher, E. von Mutius, P. Chanez, B.N. Lambrecht, and H. Hammad. 2015. Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells. Science. 349: 1106–1110.CrossRefGoogle Scholar
- 20.Youm, J., H. Lee, H.B. Chang, J. Jeon, M.H. Yoon, J.Y. Woo, M.S. Choi, Y. Hwang, S. Seong, K. Na, and J. Yoon. 2017. Justicia procumbens extract (DW2008) selectively suppresses Th2 cytokines in splenocytes and ameliorates ovalbumin-induced airway inflammation in a mouse model of asthma. Biological & Pharmaceutical Bulletin 40: 1416–1422.CrossRefGoogle Scholar
- 23.Choi, S., J. Lee, P. Kumar, K.Y. Lee, and S.K. Lee. 2011. Single chain variable fragment CD7 antibody conjugated PLGA/HDAC inhibitor immuno-nanoparticles: Developing human T cell-specific nano-technology for delivery of therapeutic drugs targeting latent HIV. Journal of Control Release 152 (Suppl 1): e9–e10.CrossRefGoogle Scholar
- 24.Reddy, K.S., B.R. Rashmi, H.J. Dechamma, S. Gopalakrishna, N. Banumathi, V.V. Suryanarayana, et al. 2012. Cationic microparticle [poly(D,L-lactide-co-glycolide)]-coated DNA vaccination induces a long-term immune response against foot and mouth disease in guinea pigs. The Journal of Gene Medicine 14: 348–352.CrossRefGoogle Scholar
- 25.Kostadinova, A.I., J. Middelburg, M. Ciulla, J. Garssen, W.E. Hennink, L. Knippels, C. van Nostrum, and L.E.M. Willemsen. 2018. PLGA nanoparticles loaded with beta-lactoglobulin-derived peptides modulate mucosal immunity and may facilitate cow’s milk allergy prevention. European Journal of Pharmacology 818: 211–220.CrossRefGoogle Scholar